OncoMatch/Clinical Trials/NCT07106710
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Is NCT07106710 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BCMA CAR-T and GPRC5D/CD3 BiTEs for multiple myeloma, newly diagnosed.
Treatment: BCMA CAR-T · GPRC5D/CD3 BiTEs — This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with ultra-high-risk multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression
Tumor cells were BCMA and GPRC5D positive
Required: GPRC5D overexpression
Tumor cells were BCMA and GPRC5D positive
Allowed: IGH t(4;14)
t(4;14)
Allowed: IGH t(14;16)
t(14;16)
Allowed: CDKN2C deletion 1p
deletion 1p
Allowed: MYC rearrangement
MYC rearrangement
Allowed: TP53 deletion 17p
deletion 17p
Allowed: TP53 mutation
TP53 mutation
Demographics
Prior therapy
Cannot have received: BCMA-targeted therapy
Prior BCMA-targeted therapy
Cannot have received: CAR-T cell therapy
Prior CAR-T therapy
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min (cockroft-gault formula)
Liver function
serum total bilirubin <2 x upper limit of normal (uln), serum ast and alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07106710 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require TNFRSF17?
Yes, TNFRSF17 overexpression is a required biomarker for enrollment.
Does this trial require GPRC5D?
Yes, GPRC5D overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages